Baseline characteristics of patients with progressive and stable disease
| Progressive disease N=63 | Stable disease N=108 | Adjusted* Univariable OR (95% CI) | p Value | |
|---|---|---|---|---|
| Sociodemographics | ||||
| Age, years, mean (SD) | 54.6 (15.5) | 52.3 (13.7) | 1.010 (0.988 to 1.032) | 0.395 |
| Female, N (%) | 46 (73) | 89 (82.4) | 1.928 (0.896 to 4145) | 0.093 |
| Body weight, kg, mean (SD) | 68.1 (14.7) | 69.8 (12.9) | 0.994 (0.970 to 1.019) | 0.633 |
| Disease characteristics, N (%) | ||||
| Friction rubs | 5 (7.9) | 1 (0.9) | 11.229 (1.247 to 101.139) | 0.031 |
| Proximal muscular weakness | 7 (11.1) | 2 (1.9) | 7.012 (1.393 to 35.313) | 0.018 |
| Pulmonary crackles | 21 (33.3) | 22 (20.4) | 2.181 (1.057 to 4.501) | 0.035 |
| MRSS, median (IQR) | 4 (2–10) | 2 (0–6) | 1.014 (1.002 to 1.082) | 0.039 |
| Laboratory investigations | ||||
| eGFR, mL/min, median (IQR) | 89 (68.7–133.3) | 87.3 (70.6–104.7) | 1.006 (0.996 to 1.015) | 0.264 |
| Cardiopulmonary investigations | ||||
| FVC % of predicted, mean (SD) | 95.5 (24.7) | 101.1 (21.4) | 0.985 (0.971 to 1.000) | 0.053 |
| DLCO % of predicted, mean (SD) | 59.4 (19.8) | 66.6 (15.7) | 0.974 (0.955 to 0.993) | 0.008 |
| Maximum VO2% of predicted, mean (SD) | 83 (26.4) | 94.2 (24.3) | 0.984 (0.974 to 0.994) | 0.002 |
| SF-36, median (IQR) | ||||
| Physical Component Summary Scale | 37.9 (27.4–46.8) | 42.6 (32.5–49.6) | 0.961 (0.931 to 0.991) | 0.012 |
| SHAQ (0–3), median (IQR)† | 0.75 (0.25–1.13) | 0.5 (0.13–0.88) | 1.788 (1.010 to 3.095) | 0.044 |
*Adjusted for previous or current treatment on baseline evaluation with cyclophosphamide, methotrexate or autologous haemopoietic stem cell transplantation.
DLCO, diffusing capacity for carbon monoxide; eGFR, estimated-glomerular filtration rate; FVC, forced vital capacity; MRSS, modified Rodnan Skin Score; SF-36, Short Form-36; SHAQ, Scleroderma Health Assessment Questionnaire; VO2, volume oxygen uptake.